Vivus Inc. (NASDAQ: VVUS) shares jumped on Wednesday after the company announced a crucial approval by the U.S. Food and Drug Administration (FDA). Specifically, the FDA approved the company’s supplemental New Drug Application (sNDA) for an improved formulation of Pancreaze.
Pancreaze is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. The pancreatic enzymes in Pancreaze act like digestive enzymes physiologically secreted by the pancreas.
The improved formulation for the Pancreaze delayed-release capsules would extend the shelf life to 35 months across all Pancreaze dosages.
Vivus has worked with Nordmark Arzneimittel, its manufacturing partner for Pancreaze, on the FDA approval pursuant to the terms of the amended contract manufacturing agreement announced in June 2019.
John Amos, CEO at Vivus, commented:
The approval of this sNDA is an important milestone for VIVUS and for the patients with [exocrine pancreatic insufficiency] we seek to treat. It highlights our ability to derive additional value from our marketed products and allows patients to store Pancreaze for longer periods of time, which may help to reduce their out-of-pocket expenses. We also expect that the 36-month shelf life will limit the amount of returned product and, over time, will lower our overall supply chain costs. We look forward to working with Nordmark and our supply chain and commercial partners on the transition to the improved formulation.
Shares of Vivus traded up about 34% to $3.09 early Wednesday, in a 52-week range of $2.10 to $5.78. The consensus price target is $10.00.
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.